DOCSLIB.ORG

Identification of Five Upregulated Genes in Transplanted

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Five Upregulated Genes in Transplanted Proc. Nati. Acad. Sci. USA Vol. 91, pp. 6463-6467, July 1994 Medical Sciences Chronic cardiac rejection: Identification of five upregulated genes in transplanted hearts by differential mRNA display (gene expreson/traplant arterlosclerosl/cardlac tnsplatatlon/polymerase chain reaction) ULRIKE UTANS*, PENG LIANG*, LAURI R. WYNERt, MoRRis J. KARNOVSKYt, AND MARY E. RUSSELL*tt§ *Cardiovascular Biology Laboratory, Harvard School of Public Health, tHarvard Medical School, and tCardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115 Communicated by Arthur B. Pardee, March 25, 1994 (receivedfor review November 18, 1993) ABSTRACT Tran t arteriosclerosis, the major man- planted heart that limits transplant survival (3, 4). Studies of festation of chronic rejection, develops after alogeneic (Lewis the process in humans have been restricted by the limited to F344) but not syngeneic (Lewis to Lewis) rat cardiac availability of tissue for analysis. Clinical specimens are transplantation. To identify transcriptionaly regulated medi- heterogeneous in their degree of chronic rejection, their ators asiated with chronic cardiac rejection, we adapted the extent of superimposed disease processes, and the period differential mRNA display technique for in vvo a nt between the time they are obtained and the time of trans- specimens. Gene tanscript patterns In four allogenec hearts plantation. Also, transplanted hearts obtained at autopsy are showing early signs of chronic rejection were compared with not suitable for analysis (which requires viable tissue), and those in two syngeneic hearts exposed to the same surgical the utility of endomyocardial biopsy specimens is limited by procedure but histologically normal. Twelve differentially ex- their small size. Moreover, the restricted extent of arterio- pressed cDNA bands were Identied. We improved the prob- sclerotic lesions that follow transplantation suggests that the ability of Ioating one or more allograft-specific cDNAs from process is locally regulated; thus, studies measuring systemic a single display band by first using recovered and reampled levels of factors implicated in chronic rejection may not PCR products as probes in RNA blot analysis. CDNA faents accurately reflect levels within the graft (5). cloned from individual bands were then used in a second RNA A heterotopic rat cardiac transplantation model (which blot analysis, which allowed for the correlation of specific results in long-term graft survival) has provided insight into mRNA scripts with cDNA clones. Five cDNA clones pro- the cellular development of chronic cardiac rejection (6, 7). duced time-dependent, allograft-specific hybridization. Se- Monocytes/macrophages accumulate in the first stage (days quence analysis demonstrated that two of these cDNAs corre- 7-30) ofarteriosclerotic thickening. In the intermediate stage sponded to unknown genes, whereas the other three repre- (days 30-75) both macrophages and smooth muscle cells sented known genes not previously associated with chronic accumulate, and in the later, more obliterative stage (after 75 rejection. The latter group included the macrophage lectin days) smooth muscle cells predominate. In previous studies specific for galactoe/N-acetylgalactomine (a cell-surface we used reverse transcription PCR to measure gene tran- receptor), the nuclear P1 gene (a homologue of a yeast repli- script levels for selected cytokine factors, and we showed cation protein), and a ubiquti n-lke gene. Our application of that interferon 'y and monocyte chemoattractant protein 1 the differential display tehnique allowed the direct identifica- transcript levels were upregulated in cardiac allografts in a tion of potential mediatos under in vivo conditions that specific and local manner (ref. 8 and M.E.R., A. F. Wallace, preserve the environment of the disease process-ncluding N. E. S. Sibinga, L.R.W., and M.J.K., unpublished data). infiltrating cell populations critical to the inflammatory re- However, chronic rejection is most likely mediated by a sponse. variety of known as well as unknown factors. Therefore we performed the present study to determine whether differen- For most genes, expression is regulated at the level of tial mRNA display could be used to identify unknown me- transcription; therefore, the evaluation of gene transcripts diators or known mediators not previously implicated in has become an important tool in the study of normal and chronic cardiac rejection. We adapted the technique to the pathologic processes. Conventional measurements ofmRNA evaluation of gene expression patterns directly in diseased transcript levels are usually confined to selected genes of tissues by comparing mRNA profiles in four arteriosclerotic interest and often require information about the gene se- rat hearts after allogeneic transplantation with those in two quence. In contrast, PCR-based differential display tech- control hearts subjected to syngeneic transplantation. Using niques circumvent this constraint by allowing comparison of 27 primer combinations, we identified two unknown and gene expression patterns between two cell populations (1) or three known genes whose expression is upregulated with time between various murine organs (2). One of the principal in hearts undergoing chronic rejection. advantages of differential display is that it permits the simul- taneous identification ofgenes that are upregulated as well as genes that are downregulated. Thus differential display has MATERIALS AND METHODS the potential to identify a spectrum of molecular factors- RNA Islation and RNA Blot Analysis. Heterotopic abdom- known and unknown-that are differentially regulated in inal cardiac transplantations were performed and samples cells under various conditions. were collected as described (8, 9). For allogeneic transplan- Little is known about molecular factors involved in the tations we used Lewis rats as graft donors and F344 rats as pathogenesis of chronic cardiac rejection. In contrast with recipients. This strain combination generates grafts that acute rejection, this multicellular process results in an oblit- survive beyond 7 days, the point after which rejection would erative neointimal thickening in the vessels of the trans- be considered chronic. The early signs ofchronic rejection- macrophage infiltration and adhesion to luminal surfaces- The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" §To whom reprint requests should be addressed at: Harvard School in accordance with 18 U.S.C. §1734 solely to indicate this fact. of Public Health, 677 Huntington Avenue, Boston, MA 02115. 6463 Downloaded by guest on September 26, 2021 6464 Medical Sciences: Utans et al. Proc. Natl. Acad. Sci. USA 91 (1994) were confirmed by histologic analysis as described (7, 9). RESULTS Syngeneic control procedures (Lewis to Lewis) were per- formed to assess the contribution of surgical manipulation to Differential mRNA Display. To identify transcriptionally the inflammatory response. Hearts were harvested at various regulated genes potentially involved in the early stages of points after transplantation and quick-frozen in liquid nitro- chronic rejection, we compared differential mRNA display gen. Total cellular RNA was extracted from heart tissue with patterns for hearts from syngeneic transplantations with RNAzol B (Tel-Test, Friendswood, TX) according to the those for hearts from allogeneic transplantations. Syngeneic manufacturer's instructions. Samples of total RNA (20 ug) hearts were normal on histologic examination, whereas 7- were fractionated in 2.2 M formaldehyde/1% agarose gels and 14-day allogeneic hearts showed luminal monocyte ad- and transferred onto nylon-supported nitrocellulose (Micron hesion and infiltration without intimal thickening (as de- Separations, Westboro, MA) by standard capillary blotting scribed previously; ref. 9). We performed PCR amplifications techniques. Specific probes were generated by labeling ream- with 27 primer combinations on all six samples and identified plified or cloned cDNA fragments with [a-32P]dCTP (random 12 PCR products, designated bands 1-12, that were differ- prime DNA labeling kit, Boehringer Mannheim). After hy- entially expressed between allogeneic and syngeneic tissue. bridization at 42TC and high-stringency washes at 600C in 0.3 Fig. 1 shows PCR amplifications obtained with three separate M NaCl/0.03 M trisodium citrate, pH 7/0.1% SDS, the blots primer combinations. Indicated are four representative PCR were exposed to Kodak X-omat AR film for 3-7 days with products (bands 1, 2, 11, and 12) that were reproducibly intensifying screens. Hybridization with a partial cDNA present in the allogeneic samples (lanes 3-6) but not in the fragment of the rat homologue of 36B4 (acidic ribosomal syngeneic samples (lanes 1 and 2) in each of the three phosphoprotein P0) was used as a loading control (10). analyses. Differential mRNA Display. Differential mRNA display RNA Blot Analysis with PCR-Ampld Fragments. To analysis was carried out as described (1, 11), except that in confirm the gene regulation patterns observed in the differ- vivo rather than in vitro samples were used and six rather than ential display study, we recovered the 12 selected bands, two samples were compared simultaneously. We studied reamplified them, and used them to probe RNA blots pre- total RNAs obtained from four allografts (two each harvested pared with RNAs from syn- and allogeneic
Load more

Recommended publications
  • 1 Supplementary Information in Vivo Mrna Display Enables
    Supplementary Information In vivo mRNA display enables Large-scale Proteomics by Next Generation Sequencing P. Oikonomou1,2,3, R. Salatino2, S. Tavazoie1,2,3* 1Department of Biological Sciences, Columbia University, New York City, New York, United States 2Department of Systems Biology, Columbia University, New York City, New York, United States 3Department of Biochemistry and Molecular Biophysics, Columbia University, New York City, New York, United States * Correspondence: P.O.: [email protected]; S.T.: [email protected] Table of Contents Methods ..................................................................................................................................... 4 Plasmid Construction .............................................................................................................. 4 Yeast Strains .......................................................................................................................... 4 In vivo mRNA display Library Generation ............................................................................... 5 Yeast cell culture .................................................................................................................... 5 Excess Coat Protein ............................................................................................................... 6 Non-Specific Functional Controls for in vivo mRNA display .................................................... 6 Whole cell lysate preparation .................................................................................................
    [Show full text]
  • In Vivo Mrna Display Enables Large-Scale Proteomics by Next Generation Sequencing
    In vivo mRNA display enables large-scale proteomics by next generation sequencing Panos Oikonomoua,b,c,1, Roberto Salatinob, and Saeed Tavazoiea,b,c,1 aDepartment of Biological Sciences, Columbia University, New York, NY 10027; bDepartment of Systems Biology, Columbia University, New York, NY 10032; and cDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY10032 Edited by Jack W. Szostak, Massachusetts General Hospital, Boston, MA, and approved August 25, 2020 (received for review February 11, 2020) Large-scale proteomic methods are essential for the functional between genotype and phenotype, whereby a protein or peptide characterization of proteins in their native cellular context. How- is linked to its encoding nucleic acid. For example, in phage ever, proteomics has lagged far behind genomic approaches in display, the nucleic acid encoding the capsid displayed peptide is scalability, standardization, and cost. Here, we introduce in vivo contained within the phage (33). The resulting collection of mRNA display, a technology that converts a variety of proteomics displayed peptides can be used for the in vitro characterization of applications into a DNA sequencing problem. In vivo-expressed protein interactions, protein engineering, and selection of human proteins are coupled with their encoding messenger RNAs antibody fragment libraries (34–36). Alternative in vitro methods (mRNAs) via a high-affinity stem-loop RNA binding domain inter- linking nucleotide information to phenotype include mRNA action, enabling high-throughput identification of proteins with display (37, 38), ribosome display (39), and yeast display (40). In high sensitivity and specificity by next generation DNA sequenc- the past decade, many of these technologies have been coupled ing.
    [Show full text]
  • In Vivo Mrna Display Enables Large-Scale Proteomics by Next Generation Sequencing
    In vivo mRNA display enables large-scale proteomics by next generation sequencing Panos Oikonomoua,b,c,1, Roberto Salatinob, and Saeed Tavazoiea,b,c,1 aDepartment of Biological Sciences, Columbia University, New York, NY 10027; bDepartment of Systems Biology, Columbia University, New York, NY 10032; and cDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY10032 Edited by Jack W. Szostak, Massachusetts General Hospital, Boston, MA, and approved August 25, 2020 (received for review February 11, 2020) Large-scale proteomic methods are essential for the functional between genotype and phenotype, whereby a protein or peptide characterization of proteins in their native cellular context. How- is linked to its encoding nucleic acid. For example, in phage ever, proteomics has lagged far behind genomic approaches in display, the nucleic acid encoding the capsid displayed peptide is scalability, standardization, and cost. Here, we introduce in vivo contained within the phage (33). The resulting collection of mRNA display, a technology that converts a variety of proteomics displayed peptides can be used for the in vitro characterization of applications into a DNA sequencing problem. In vivo-expressed protein interactions, protein engineering, and selection of human proteins are coupled with their encoding messenger RNAs antibody fragment libraries (34–36). Alternative in vitro methods (mRNAs) via a high-affinity stem-loop RNA binding domain inter- linking nucleotide information to phenotype include mRNA action, enabling high-throughput identification of proteins with display (37, 38), ribosome display (39), and yeast display (40). In high sensitivity and specificity by next generation DNA sequenc- the past decade, many of these technologies have been coupled ing.
    [Show full text]
  • Mrna Display Is a Versatile Selection Method for the Generation of Novel
    Chapter 1: Introduction and overview 2 Diverse combinatorial protein libraries have the potential to generate molecules which can bind virtually any desirable target. The number of potential protein targets is enormous; including post translational modifications and alternative splicing, the human proteome contains millions of proteins (1). Including microbial proteins, the number of useful targets is even greater. The natural diversity represented by the mammalian immune system has long been exploited for the generation of novel affinity reagents (2). In vitro selection techniques such as phage display, ribosome display, and mRNA display have been developed for generation of novel protein affinity reagents as an alternative to animal immunization (3). With the advent of these techniques, synthetic and semi- synthetic immunoglobulin libraries have been developed (4-6). One drawback of using antibodies as affinity reagents, however, is that antibody immunoglobulin domains require intrachain disulfide bonds for stability (7). This requirement makes antibodies difficult to express in large quantities and also limits their utility for intracellular applications. In conjunction with the development of in vitro selection techniques, there has been interest in the generation of alternative protein scaffolds which, like antibodies, are able to tolerate sizable sequence diversity but, unlike antibodies, also express well in the intracellular environment (3, 8, 9). There are many applications for the molecular recognition of natural proteins by novel protein affinity reagents (10). Recombinant antibodies are becoming increasingly common as therapeutics (11). Other applications include standard laboratory techniques such as immunoprecipitation, ELISA, western blot, and immunofluorescence microscopy. Applications for protein detection are expanding with the development of 3 ultra-sensitive nano-electonic devices (12) and the use of engineered antibodies in nuclear medicine (13).
    [Show full text]
  • PURE Mrna Display and Cdna Display Provide Rapid Detection Of
    PURE mRNA display and cDNA display provide rapid detection of consensus binding motif via high-throughput sequencing Sabrina Galinanes Reyes1, Yutetsu Kuruma2, Mai Fujimi3, Masako Yamazaki4, Sumie Eto4, Satoshi Tamaki4, Asaki Kobayashi5, Ryo Mizuuchi6, Lynn Rothschild7, Mark Ditzler7, and Kosuke Fujishima3 1University of Glasgow 2Japan Agency for Marine-Earth Science and Technology 3Tokyo Institute of Technology 4MOLCURE, Inc 5INSERM 6JST 7NASA Ames Research Center June 4, 2020 Abstract The recombinant in vitro translation system known as the PURE system has been used in a variety of cell-free experiments such as expression of native and de novo proteins as well as various display methods to select for functional polypeptides. We developed a refined PURE-based display method for the preparation of stable mRNA and cDNA-peptide conjugates and validated its utility for in vitro selection. Our conjugate formation efficiency exceeded 40%, followed by gel purification to allow minimum carry-over of components from the translation system to the downstream assay enabling clean and efficient random peptide sequence screening. As a proof-of-concept, we chose the commercially available anti-FLAG M2 antibody as a target molecule for validation. Starting from approximately 1.7 x 1012 random sequences, a round-by-round high-throughput sequencing showed clear enrichment of the FLAG epitope DYKDDD as well as revealing consensus FLAG binding motif DYK(D/L/N)(L/Y/D/N/F)D. Enrichment of core FLAG motifs lacking one of the four key residues (DYKxxD) indicates that Tyr (Y) and Lys (K) appear as the two key residues essential for binding. Furthermore, comparison between mRNA display and cDNA display method resulted in overall similar performance with slightly higher enrichment for mRNA display.
    [Show full text]
  • Chapter 2 Mrna Display
    8 Chapter 2 mRNA Display: Ligand Discovery, Interaction Analysis and Beyond This work has been adapted from the following publication: Takahashi, T.T., Austin, R.J. and Roberts, R.W. mRNA display: ligand discovery, interaction analysis and beyond. (2003) Trends Biochem Sci 28, 159-165. 9 Abstract In vitro peptide and protein selection using mRNA display* enables the discovery and directed evolution of new molecules from combinatorial libraries. These selected molecules can serve as tools to control and understand biological processes, enhance our understanding of molecular interactions, and potentially treat disease in therapeutic applications. In mRNA display, mRNA molecules are covalently attached to the peptide or protein they encode. These mRNA-protein fusions enable in vitro selection of peptide and protein libraries of more than 1013 different sequences. mRNA display has been used to discover novel peptide and protein ligands for RNA, small molecules, and proteins, as well as to define cellular interaction partners of proteins and drugs. In addition, several unique applications are possible with mRNA display, including self-assembling protein chips and library construction with unnatural amino acids, and chemically modified peptides. *mRNA display has been referred to as mRNA-protein fusions (1), in vitro virus and in vitro virus virion (2), and PROfusionTM technology (3). 10 Introduction Functional approaches, such as in vitro selection, currently provide the best means available for isolating peptides and proteins with desired chemical or biochemical properties. Over the last decade, display technologies have been essential tools in the discovery of peptide and protein ligands and in delineating in vivo interaction partners. The phage (4) and ribosome display systems (5) have been principally used for discovery, while the yeast two-hybrid method (6) has been used for in vivo interaction analysis.
    [Show full text]
  • Molecular Analysis and Genome Discovery Final Proof 31.3.2004 3:42Pm Page I
    Rapley/Molecular Analysis and Genome Discovery Final Proof 31.3.2004 3:42pm page i Molecular Analysis and Genome Discovery Molecular Analysis and Genome Discovery edited by Ralph Rapley and Stuart Harbron ß 2004 John Wiley & Sons, Ltd ISBN 0 471 49847 5 (cased) ISBN 0 471 49919 6 (pbk) Rapley/Molecular Analysis and Genome Discovery Final Proof 31.3.2004 3:42pm page iii Molecular Analysis and Genome Discovery Edited by Ralph Rapley University of Hertfordshire, UK and Stuart Harbron The Enzyme Technology Consultancy, UK Rapley/Molecular Analysis and Genome Discovery Final Proof 31.3.2004 3:42pm page iv Copyright ß 2004 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (þ44) 1243 779777 Email (for orders and customer service enquiries): [email protected] Visit our Home Page on www.wileyeurope.com or www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [email protected], or faxed to (þ44) 1243 770620. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered.
    [Show full text]
  • Discovery of Membrane-Permeating Cyclic Peptides Via Mrna Display John Bowen1†, Allison E
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.20.212142; this version posted July 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Discovery of membrane-permeating cyclic peptides via mRNA display John Bowen1†, Allison E. Schloop2, Gregory T. Reeves3, Stefano Menegatti1,4,*, and Balaji M. Rao1,4,* 1 Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way room 2-009, Raleigh, NC 27606 2 Genetics Program, North Carolina State University, 112 Derieux Place, Raleigh, NC 27695 3 Department of Chemical Engineering, Texas A&M University, 200 Jack E. Brown Engineering Building, College Station, TX 77843 4 Biomanufacturing Training and Education Center (BTEC), North Carolina State University, 850 Oval Dr, Raleigh, NC 27606 *Corresponding authors: [email protected]; [email protected]. Short Running title: cyclic peptide vectors for non-disruptive access of embryos and cells Abstract. Small synthetic peptides capable of crossing biological membranes represent valuable tools in cell biology and drug delivery. While several cell-penetrating peptides (CPPs) of natural or synthetic origin have been reported, no peptide is currently known to cross both cytoplasmic and outer embryonic membranes. Here we describe a method to engineer membrane-permeating cyclic peptides (MPPs) with broad permeation activity by screening mRNA display libraries of cyclic peptides against embryos at different developmental stages. The proposed method was demonstrated by identifying peptides capable of permeating Drosophila melanogaster (fruit fly) embryos and mammalian cells. The selected peptide cyclo[Glut-MRKRHASRRE-K*] showed a strong permeation activity of embryos exposed to minimal permeabilization pretreatment, as well as human embryonic stem cells and a murine fibroblast cell line.
    [Show full text]
  • Mrna Display: from Basic Principles to KEYNOTE REVIEW
    Drug Discovery Today Volume 00, Number 00 November 2013 REVIEWS An emerging combinatorial technology harnesses the ribosome to access unnatural peptide chemical space for the rapid discovery of novel macrocycles. mRNA display: from basic principles to KEYNOTE REVIEW macrocycle drug discovery Reviews 1 1 2 Kristopher Josephson Kristopher Josephson , Alonso Ricardo and Jack W. Szostak Kristopher Josephson received his PhD in Micro- 1 Ra Pharmaceuticals, One Kendall Square, Suite B14301, Cambridge, MA 02139, USA biology from the University 2 of Alabama at Birmingham. Howard Hughes Medical Institute, Department of Molecular Biology, and Center for Computational For his dissertation and Integrative Biology, Massachusetts General Hospital, 185 Cambridge St, Boston, MA 617-726-5981, USA research with Mark R. Walter he employed pro- tein crystallography and We describe a new discovery technology that uses mRNA-display to rapidly protein engineering to study cytokine signaling. As a postdoctoral fellow with synthesize and screen macrocyclic peptide libraries to explore a valuable Jack W. Szostak at Harvard University he studied the region of chemical space typified by natural products. This technology ribosomal incorporation of unnatural amino acids into peptides. He then joined Merck-Serono’s crystallogra- allows high-affinity peptidic macrocycles containing modified backbones phy and computational chemistry group working on kinase inhibitor projects in oncology. Kris is currently and unnatural side chains to be readily selected based on target binding. Director of Molecular Biology at Ra Pharmaceuticals, which uses in vitro selection for the discovery of novel Success stories covering the first examples of these libraries suggest that peptide therapeutics. His interests include structural they could be used for the discovery of intracellular protein–protein biology, protein engineering, drug discovery and in vitro selection technologies.
    [Show full text]
  • In Vitro Selection of Peptides and Proteins Advantages of Mrna
    pubs.acs.org/synthbio Review In Vitro Selection of Peptides and ProteinsAdvantages of mRNA Display Matilda S. Newton, Yari Cabezas-Perusse, Cher Ling Tong, and Burckhard Seelig* Cite This: https://dx.doi.org/10.1021/acssynbio.9b00419 Read Online ACCESS Metrics & More Article Recommendations ABSTRACT: mRNA display is a robust in vitro selection technique that allows the selection of peptides and proteins with desired functions from libraries of trillions of variants. mRNA display relies upon a covalent linkage between a protein and its encoding mRNA molecule; the power of the technique stems from the stability of this link, and the large degree of control over experimental conditions afforded to the researcher. This article describes the major advantages that make mRNA display the method of choice among comparable in vivo and in vitro methods, including cell-surface display, phage display, and ribosomal display. We also describe innovative techniques that harness mRNA display for directed evolution, protein engineering, and drug discovery. KEYWORDS: protein engineering, in vitro selection, mRNA display, phage display, unnatural amino acids, ribosome display mRNA display is an in vitro selection and directed evolution technique that enables the screening of trillions of protein variants for desired functions in a single experiment. In directed evolution, researchers working to alter binding or catalytic properties of a target protein or peptide have a range of in vitro and in vivo techniques at their disposal to isolate their desired variant from large mixtures of variants. The goal of this review is to highlight the unique advantages of mRNA display that make this method superior to most other directed evolution techniques.
    [Show full text]
  • UNIT – I - Fundamentals of Genomics and Proteomics– SBI1309
    Genome organization and sequencing SCHOOL OF BIO AND CHEMICAL ENGINEERING DEPARTMENT OF BIOTECHNOLOGY UNIT – I - Fundamentals of Genomics and Proteomics– SBI1309 1 Genome organization and sequencing Organization of prokaryotic and eukaryotic genomes Prokaryotic Usually circular Smaller Found in the nucleoid region Less elaborately structured and folded Eukaryotic Complexed with a large amount of protein to form chromatin Highly extended and tangled during interphase Found in the nucleus The current model for progressive levels of DNA packing: Nucleosome basic unit of DNA packing formed from DNA wound around a protein core that consists of 2 copies each of the 4 types of histone (H2A, H2B, H3, H4)] A 5th histone (H1) attaches near the bead when the chromatin undergoes the next level of packing 30 nm chromatin fiber next level of packing; coil with 6 nucleosomes per turn the 30 nm chromatin forms looped domains, which are attached to a nonhistone protein scaffold (contains 20,000 – 100,000 base pairs) Looped domains attach to the inside of the nuclear envelope the 30 nm chromatin forms looped domains, which are attached to a nonhistone protein scaffold (contains 20,000 – 100,000 base pairs) 2 Genome organization and sequencing 3 Genome organization and sequencing Histones influence folding in eukaryotic DNA. Histones small proteins rich in basic amino acids that bind to DNA, forming chromatin Contain a high proportion of positively charged amino acids which bind tightly to the negatively charged DNA Heterochromatin Chromatin
    [Show full text]
  • Efficient in Vitro Expression of Aglycosylated Full-Length Igg Using
    Efficient in vitro expression of aglycosylated full-length IgG using a reconstituted cell-free protein synthesis system, PUREfrex® 2.0 ○ Satoshi Murakami, Rena Matsumoto, Takashi Kanamori For more information, please contact us. URL: www.genefrontier.com GeneFrontier Corporation (Chiba, Japan) E-mail: [email protected] Abstract: Aglycosylated full-length IgG (anti-HER2 monoclonal antibody) was synthesized using PURE frex 2.0 . The PURE (Protein synthesis Using Recombinant Elements) system is a reconstituted cell-free protein synthesis system, which consists of only purified factors necessary for transcription, translation and energy regeneration. Recently, we developed an updated PURE system with higher productivity, which was launched as “PURE frex 2.0 ” in 2015. We reported that PURE frex 2.0 could be used for production of functional proteins such as Fab, scFv, a protein based toxin and an immunotoxin last year. Here, we report the further application using PURE frex 2.0 for production of IgG. To synthesize IgG, we optimized the composition of the reaction mixture and the reaction conditions as below; 1) adding molecular chaperone (DnaK mix) to increase the solubility of the product; 2) adding DsbC to form disulfide bonds between the correct cysteine residues; 3) adjusting GSH/GSSG ratio for optimum redox state; 4) long-time incubation (over 20h) to assemble the hetero tetramer of two heavy chains and two light chains. At the best mode of synthesis, the productivity of IgG reached to 0.042 mg/mL. The synthesized IgG was detected as single band on non-reduced SDS-PAGE after the purification by protein A resin and the following gel filtration.
    [Show full text]